SUB: Submission of Annual Report for the FY 2025-26 comprising of the Notice of Annual General Meeting, Directors Report, Independent Auditors Report and Audited Financial Statements

APTUS PHARMA LIMITED Date: 21.08.2026 The BSE Ltd Phiroze Jeejeebhoy Tower, Dalal Street, Mumbai – 400001 SECURITY CODE: 544529 Dear Sir, SUB: Submission of Annual Report for the FY 2025-26 comprising of the Notice of Annual General Meeting, Directors Report, Independent Auditors Report and Audited Financial Statements Dear Sir/Madam, With reference to the above, we wish to inform you that the 16th Annual General Meeting ("AGM") of Aptus Pharma Limited ("the Company") will be held on 14th September, 2026 at 11:00 A.M. (IST) through Video Conferencing ("VC") / Other Audio-Visual Means ("OAVM"). Pursuant to Regulation 30 and 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Annual Report of the Company for the Financial Year 2025-26, including the Notice convening the 16th AGM. The Annual Report is also available on the website of the Company at https://aptus- pharma.com/aptus-annual-report/ Kindly take the same on record. Thanking you, Yours faithfully, For Aptus Pharma Limited Tejash Hathi Managing Director DIN: 03151221 Regd. Address: Ashutosh Buildcon, Opp. Slok – 2, Nr. Harikrupa Logistic Park, Aslali, Daskroi, Ahmedabad, Gujarat – 382427, India Contact: 76004 27827, E-mail: aptuspharma@rediffmail.com, Website: www.aptus-pharma.com CIN: U24230GJ2010PLC061957, GSTIN: 24AAICA7890D1ZM ANNUAL REPORT (2025-26) We Deliver Quality & Innovation to Redefine Human Lives Annual Report (2025 - 26) Registered Office: Ashutosh Buildcon, Opp. Slok-2, Nr. Harikrupa Logistic Park, Aslali, Daskroi, Ahmedabad, Gujarat – 382427 Head Office: RK Trade Tower, Wing-A, Office No. 616 to 619, Near Sheetal Park Circle, 150 Ft. Ring Road, Rajkot, Gujarat – 360006 Corporate Office: Shree Building 1st Floor, Opp. Satya Sai Hospital, Kalawad Road, Rajkot – 360005, Gujarat aptuspharma@rediffmail.com | info@aptuspharma.com www.aptus-pharma.com Statutory Auditors: Bankers: M/s A B K B & Co., Chartered Accountants, ICICI Bank Rajkot (FRN: 136695W) Secretarial Auditors: RTA: M/s. JPMK & Associates, Practising Accurate Securities & Registry Private Company Secretaries, Rajkot Limited, Ahmedabad Listed at: ISIN: BSE SME Platform INE15XJ01010 BOARD OF DIRECTORS TEJASH M. HATHI CHETAN S. LALSETA RIDDHISH N. TANNA (DIN: 03151221) (DIN: 02547012) (DIN: 03231612) Managing Director Director Director JYOTIBEN H. VIKAS R. JOBANPUTRA SEJAL HARIT PALAN CHANDARANA (DIN: 10921323) (DIN: 10893463) (DIN: 10607059) Independent Director Independent Director Director www.aptus-pharma.com Annual Report (2025 - 26) ABOUT THIS REPORT: This Annual Report provides a comprehensive overview of Aptus Pharma Limited’s performance, progress, and priorities during the financial year 2025–26. This report provides information about the financial and operational performance of our business, as mandated by the authorities under the Companies Act, 2013, such as Ministry of Corporate Affairs, SEBI, Stock Exchanges and other regulatory bodies. It also provides insights into our strategic priorities and the opportunities and challenges shaping the pharmaceutical industry. FORWARD-LOOKING STATEMENTS This Annual Report has been prepared by the Company and contains information derived from sources that the Company believes to be reliable. Certain statements contained in this Annual Report may constitute “forward-looking statements” within the meaning of applicable securities laws and regulations. These forward-looking statements are based on the management’s current expectations, estimates, assumptions and assessments concerning future events and circumstances. Such statements are subject to various risks, uncertainties and other factors, many of which are beyond the control of the Company, that could cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements may generally be identified by words or expressions such as “believes”, “estimates”, “anticipates”, “expects”, “intends”, “may”, “will”, “plans”, “outlook”, “seeks”, “foresees”, “aims”, “likely”, “projects” and other words or expressions of similar meaning in connection with a discussion of future operational or financial performance. The risks and uncertainties relating to these statements include, but are not limited to, fluctuations in earnings, the Company’s ability to manage growth and implement its business strategies, competition, changes in input and operating costs, wage increases, the ability to attract and retain skilled personnel, changes in market conditions, technological developments, natural calamities, epidemics and pandemics, political or economic instability, changes in laws and regulations, foreign exchange fluctuations, restrictions on the raising of capital, protection and unauthorised use of intellectual property and general economic and business conditions affecting the industry in which the Company operates. The Company cannot provide any assurance that the expectations reflected in such forward-looking statements will prove to be correct. Readers are cautioned not to place undue reliance on these forward-looking statements, which are based on the information available to the Company as of the date of this Annual Report. The Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as may be required under applicable laws and regulations. www.aptus-pharma.com Annual Report (2025 - 26) CONTENTS Description Page No. Strategic Review Message from the Managing Director 01 - 03 Company Overview 04 Core values and purpose 05 Business Structure & Verticals 06 Key Milestones 07 Our leadership & management 08 Business Process Flow 09 flagship brands & leading 10 Brands-figures of 2025-26 Global & Indian pharmaceutical industry 11 - 12 Financial performance 13 - 14 Strategic growth roadmap 15 Notice of the AGM 16 - 50 Directors Report 51 - 65 Annex. -1: Secretarial Audit Report 66 - 71 Annex. -2: Statement of Disclosure of Remuneration 72 - 74 Annex. -3: Management Discussion and Analysis Report 75 - 83 Annex. -4: CEO & CFO Compliance Certificate 84 Auditors Report 85 - 94 Financial statement 95 - 118 www.aptus-pharma.com Annual Report (2025 - 26) MESSAGE FROM THE MANAGING DIRECTOR Dear Shareholders, It is with great pride and a deep sense of responsibility that I welcome you to the 16th Annual Report of Aptus Pharma Limited—the first Annual Report since your Company became a publicly listed entity. The successful completion of the Company’s maiden Initial Public Offering, comprising a fresh issue of 18,60,000 equity shares of ₹10 each at an issue price of ₹70 per share, including a securities premium of ₹60 per share, aggregating ₹1,302.00 lakh, and the subsequent listing of the Company’s equity shares on the BSE SME Platform with effect from 30th September, 2025, marked a defining milestone in our journey. Your trust and participation in the IPO have provided us with additional resources and confidence to pursue our growth plans responsibly. FY 2025-26—A Landmark Year The financial year under review marked a significant improvement in the Company’s scale of operations and profitability. Revenue from operations increased to ₹4,657.46 lakh from ₹2,455.77 lakh in the preceding financial year, representing growth of approximately 89.65%. Profit after tax increased to ₹461.99 lakh from ₹309.96 lakh in the preceding financial year, representing growth of approximately 49.05%. This performance reflects the benefits of increased scale, higher sales volumes, expansion of the product portfolio and the Company’s continued focus on operational and cost discipline. TEJASH M. HATHI Managing Director www.aptus-pharma.com 01 Annual Report (2025 - 26) Driving Growth Through Product Expansion Expansion of the product portfolio continued to be an important contrib [Showing first 8,000 characters — download PDF for full document]